Egg and Soy-Derived Peptides and Hydrolysates: A Review of Their Physiological Actions against Diabetes and Obesity

Stepheny C. de Campos Zani 1, Jianping Wu 2,* and Catherine B. Chan 1,2,*

1 Department of Physiology, University of Alberta, Edmonton, AB T6G 2R3, Canada; zani@ualberta.ca
2 Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton, AB T6G 2R3, Canada
* Correspondence: jwu3@ualberta.ca (J.W.); cbchan@ualberta.ca (C.B.C.);
Tel.: +1-780-492-6885 (J.W.); +1-780-492-9964 (C.B.C.)

Received: 23 March 2018; Accepted: 26 April 2018; Published: 28 April 2018

Abstract: Type 2 diabetes and obesity are two chronic conditions associated with the metabolic syndrome and their prevalences are increasing worldwide. The investigation of food protein-derived bioactive peptides that can improve the pathophysiology of diabetes or obesity while causing minimal side effects is desired. Egg and soy proteins generate bioactive peptides with multiple biological effects, exerting nutritional and physiological benefits. This review focuses on the anti-diabetic and anti-obesity effects of egg- and soy-derived peptides and hydrolysates in vivo and in vitro relevant to these conditions. Studies using the intact protein were considered only when comparing the results with the hydrolysate or peptides. In vivo evidence suggests that bioactive peptides from egg and soy can potentially be used to manage elements of glucose homeostasis in metabolic syndrome; however, the mechanisms of action on glucose and insulin metabolism, and the interaction between peptides and their molecular targets remain unclear. Optimizing the production of egg- and soy-derived peptides and standardizing the physiological models to study their effects on diabetes and obesity could help to clarify the effects of these bioactive peptides in metabolic syndrome-related conditions.

Keywords: diabetes; obesity; egg; soy; peptides; hydrolysate; bioactive peptides

1. Introduction

Diabetes is a chronic disease marked by the presence of hyperglycemia that occurs when the pancreas cannot produce enough insulin, or the body cannot effectively use the insulin that is produced. Uncontrolled diabetes can lead to several serious complications such as cardiovascular disease, nephropathy, retinopathy, amputation and nerve damage [1,2]. Well-managed diabetes can reduce the risk of these complications and increase life expectancy [1]. The treatment of diabetes requires long-term self-management and adherence to therapy, but several commonly used drugs can cause side-effects, which could negatively impact adherence [3].

Identifying natural products that can improve the disease state while exerting fewer side-effects is a current research trend. Many studies have explored the potential of biologically active peptides derived from food sources, which could be referred to as functional food ingredients. In the absence of a common definition, The European Commission Concerted Action on Functional Food Science in Europe together with The International Life Sciences Institute Europe published a consensus document and defined functional foods as those that beyond their nutritional value can exert one or more physiological effects in the body in a manner that can improve health/well-being or reduce the risk of diseases [4]. These peptides are produced enzymatically or using fermentation under controlled conditions of pH and temperature.
Two interesting sources of bioactive peptides are hen egg and soy. Egg is relatively cheap, found in almost every country and is nutrient-dense, which means it could be affordable and beneficial to a broad range of the world’s population. Although the physiological effects of egg hydrolysates (EH) and peptides have been tested, the majority of publications investigated the angiotensin converting enzyme (ACE)-inhibitory, antioxidant or anti-inflammatory effects as reviewed by Liu et al. [5]. Soy, which is also protein-dense and broadly available, has been mostly studied regarding its antioxidant and anti-inflammatory actions as reviewed by Masilamani et al. [6]. Since an upregulated renin angiotensin system, inflammation and oxidative stress are observed in obesity and diabetes, which in turn are components of the metabolic syndrome (MetS) along with hypertension, it is of interest to study egg and soy in terms of their anti-diabetic and anti-obesity properties.

This review focuses on the effects of EH and soy hydrolysate (SH) or peptides in improving or preventing type 2 diabetes (T2D) and obesity in vivo or relevant in vitro endpoints such as insulin signaling pathways. The inclusion criteria were studies using egg, egg white (EW), egg yolk or soy in the form of hydrolysate or peptides. Studies where the results of intact protein were compared to the hydrolysate were also included. Only studies using oral administration of the hydrolysate or peptides in vivo were considered.

2. Diversity of Bioactive Peptides

Although several processes can be used to generate bioactive peptides, the most common method is enzymatic hydrolysis. Substrate specificity of enzymes generates peptides of different amino acid sequences and can be used to optimize the production of peptides with desired biological effects, as can be seen in Tables 1–4. Nevertheless, the peptides are complex and the use of a purification step following hydrolysis is common [7–9]. Alternatively, synthetic production of peptides [10,11] can be used to obtain specific peptides and study their physiological action.

Several groups have used the whole hydrolysate instead of individual peptides when studying their effects [12–18]. In those cases, effects cannot be attributed to a specific peptide, because the enzymatic hydrolysis can generate a myriad bioactive peptides, raising the possibility that the effect observed could be due to a combination of numerous peptides presented in the hydrolysate. Another variable of enzymatic hydrolysis process is the processing duration, which can impact both the peptide sequences and concentration in the hydrolysate [19].

It is worth mentioning that some of the enzymes used in hydrolysate production are not naturally produced by the human body, such as thermoase [20], flavourzyme [8,19] and neutrase [19], which means the peptides produced may not replicate those generated by the natural digestion process in the human body. Even though some studies used enzymes that are naturally produced in humans, such as pepsin and pancreatin [7,11,15,17] there is also no guarantee that the desired peptides would be produced or stable after further gastrointestinal digestion.

Due to the diversity of peptides obtained after enzymatic hydrolysis, multiple mechanisms of action of the peptides may influence outcomes. The length of the peptides can influence the absorption process in the gut as reviewed by Miner-Williams et al. [21] and specific amino acids can have a greater influence in the interaction with enzymes, for example the regions of interaction between a soy peptide and the enzyme dipeptidyl peptidase-IV (DPP-IV) correlated with the presence of the amino acids glutamine and arginine [11].

There is little evidence that accounts for the mechanisms of action of the peptides and important questions remain unanswered. For instance, are the peptides absorbed intact? Or can they initiate a cascade reaction by binding to receptors in the gut cells? Is the integrity and stability of the peptides after gastrointestinal digestion a requirement for them to exert their physiological effects?

3. In Vitro Study of Egg Hydrolysate (EH)/Peptides

A summary of in vitro studies and identified peptide sequences are provided in Table 1. Multiple metabolic pathways in several organs are involved in glucoregulation. One possibility to help
To manage diabetes is inhibition of intestinal $\alpha$-glucosidase, which is an effective method to delay carbohydrate absorption [22] and reduce blood glucose concentrations. Peptides obtained after pepsin hydrolysis of egg white (EW) exhibited $\alpha$-glucosidase IC$_{50}$ values ranging from 365 to 1694 $\mu$g/mL [7], while peptides obtained from alcalase hydrolysis of egg yolk yielded IC$_{50}$ values ranging from 23 to 40 $\mu$mol/L [22]. Beside $\alpha$-glucosidase inhibition, the peptides from EW exerted multiple activities, for instance, ACE-inhibitory capacity with IC$_{50}$ ranging from 9 to 27 $\mu$g/mL and DPP-IV- inhibitory activity with IC50 from 223 to 1402 $\mu$g/mL. The only exception was the peptide YIEAVNKVSPRAGQPF, which did not present either $\alpha$-glucosidase or DPP-IV inhibitory activity [7]. The results suggest that egg peptides can potentially exert more than one physiological effect. Multiple activities exerted by the egg white hydrolysate (EWH) were found in other studies using cell lines as well [19,20]. EWH obtained with different enzymes (Table 2) exerted concomitantly anti-inflammatory, antioxidant, hypocholesterolemic, DPP-IV- and ACE-inhibitory activity [19]. The EWH derived from pepsin and peptidase-mediated hydrolysis had the highest potential against disorders associated with MetS such as hypertension, obesity and T2D, presenting IC$_{50}$ against DPP-IV of <10 mg protein/mL and against ACE ranging from 47 to 151 $\mu$g/mL [19].

In the 3T3-L1 adipocyte cell line, thermoase + pepsin-prepared EWH not only sensitized the cells to insulin action but also mimicked insulin signaling. The EWH stimulated adipocyte differentiation by enhancing peroxisome proliferator associated receptor gamma (PPAR-$\gamma$) and CAAT/enhancer binding protein alpha (C/EBP$\alpha$) expression, which led to enhanced adiponectin release and intracellular lipid accumulation. Moreover, these EWH enhanced the phosphorylation of proteins involved in the insulin signaling pathway, such as extracellular signal regulated kinase 1/2 (ERK 1/2), insulin receptor substrate 1 (IRS-1) and insulin receptor and protein kinase B (AKT) [20]. In adipocytes, the same EWH also presented anti-inflammatory properties by reducing cyclooxygenase-2 (COX-2) expression and C-Jun phosphorylation induced by tumor necrosis factor-$\alpha$ (TNF-$\alpha$) [20]. Thus, the effect of thermoase + pepsin-prepared EWH in 3T3-L1 cells is exerted via insulin receptor and downstream proteins in the insulin signaling pathway. The adipogenic effect observed was partially mediated by PPAR-$\gamma$, because peptides identified in the hydrolysate upregulated PPAR-$\gamma$ expression in vitro [20]. In macrophages, no effects were observed regarding TNF-$\alpha$ using peptidase or pepsin or flavourzyme EWH, but peptidase-prepared EWH reduced IL-6 after lipopolysaccharides stimulation [19].

An improvement in insulin sensitivity was also observed in a muscle cell line exposed to EW peptides. IRW, a peptide from egg ovotransferrin improved insulin resistance induced by angiotensin-II in skeletal muscle cells [10]. The peptide reversed the impaired insulin signaling and glucose uptake by normalizing phosphorylation of the serine residue in IRS and increasing AKT phosphorylation, which contributed to increased translocation of glucose transporter 4 (GLUT4) to the plasma membrane. It was shown that these effects were exerted partly by reducing angiotensin II type 1 receptor expression and reactive oxygen species (ROS) production [10]. In contrast, IQW and LPK egg white-derived peptides only exhibited antioxidant activity [10].

Although anti-diabetic activity is exerted by specific peptides, others presented low or no activity as antidiabetic agents [7,10,19,22], a fact that was attributed to their different amino acid sequences once they all were tested under the same conditions [10,19]. This fact indicates that the effects observed were due to the presence of specific peptides; however, there is a lack of experiments studying the relationship between the amino acid sequence in the peptides and their actions.

In summary, in vitro studies show that EWH or peptides derived from EW and egg yolk can exert multiple biological activities, including antidiabetic, by inhibiting enzymes such as DDP-IV and $\alpha$-glucosidase or improving insulin sensitivity or signaling. However, the peptide amino acid sequence is important in determining the peptides’ ability to act as antidiabetic agents. Therefore, there is a need for more in vitro experiments to specifically identify the interaction between the peptides, their amino acid sequence and the targets involved in the insulin signaling pathway.
Table 1. In vitro studies of egg-derived hydrolysates/peptides and their effects related to diabetes and obesity.

| Aims | Hydrolysis | Main Findings | Additional Assays | Peptides |
|------|------------|---------------|------------------|----------|
| **Egg yolk specific peptides** | | | Enzymatic activity | |
| Enzymatic activity | Pepsin (120 min) | Three out of four peptides ↓ ACE, α-glucosidase and DPP-IV activity. The peptides presented antioxidant and ion chelating activity. | DPPH - radical scavenging | YINQMPQKSRE YINQMPQKSEQEA VTGRFGHYQAQ YIEAVNVSPRAQPF |
| **Egg white specific peptides** | | | Enzymatic activity | |
| Enzymatic activity | Alcalase (180 min) | Peptides from EW ↓ α-glucosidase but not α-amylase. | N/A | Ovotransferrin RVPSLM TSPSR DLKQK AGLAPY Ovalbumin RVPSL DHPLFL HACN WIGL |
| **Egg white specific peptides** | | | Cell culture | |
| Cell culture | Alcalase, Flavourzyme, Neutrase, Trypsin, Pepsin, Pancreatin Peptidase Promod 144P (0, 2, 4, 8, 12, 24, 36 and 48 h) | Peptidase hydrolysate: ↓ ROS, CHOL and IL-6. Peptidase hydrolysate (24 h) Hypcholesterolemic activity 0.154 ± 0.011 (mmol bound/mg protein) ORAC test 574.2 ± 4.0 (µmol Trolox/g protein) Peptidase hydrolysate (24 h) ↓ COX-2 and TNF-α-mediated C-Jun phosphorylation. ↑ p-AKT after insulin treatment. | Peptidase hydrolysate (24 h) LDEQVG DOKKVE GVDKTS IEGSVHQA GGVYVT |
| | | | | ERYPIL VFKGL WEKAFAKDQ AMPFRY TEQE |

Abbreviations: ACE, angiotensin converting enzyme; Ang-II, Angiotensin II; DPP IV, Dipeptidyl peptidase IV; EW, Egg white; IRS-1, Insulin receptor substrate 1; IRS, Insulin receptor; IRβ, Insulin receptor β; COX-2, cyclooxygenase 2; PPARy, peroxisome proliferator associated receptor gamma; C/EBP-α, CAAT/enhancer binding protein alpha; AKT, protein kinase B; ERK1/2, Extracellular signal regulated kinase 1/2; TNF-α, Tumor necrosis factor alpha; DPPH, 1,1-diphenyl-2-picrylhydrazyl; ROS, Reactive oxygen species; CHOL, Cholesterol; IL-6, Interleukin 6; GLUT4, Glucose transporter 4; AT1R, Angiotensin II type 1 receptor; AT2R, Angiotensin II type 2 receptor; ↑ enhanced/stimulated; ↓ reduced/inhibited.
4. In Vivo Studies of Egg White Hydrolysate (EWH)/Peptides

In vivo EWH presents multiple biological activities as demonstrated in Table 2. All these in vivo studies were done in rodents and the specific peptides in EWH were not reported. Although no changes were found in circulating insulin, one study observed a reduction in blood glucose concentration and reduced homeostasis model assessment of insulin resistance (HOMA-IR) with protease-prepared EWH treatment [12]. Another three studies reported no changes in blood glucose levels with EWH obtained from protease and alcalase hydrolysis [13,23,24]. Serum leptin concentrations were not statistically different [23,24], and reduction or no changes were observed in plasma adiponectin levels [12,14].

Alongside enlarged adipose tissue, ectopic fat accumulation can lead to insulin resistance (IR) and consequently T2D. Analysis of the lipid content in liver and muscle, and total body fat percentage in rats showed reduced values after protease- and pepsin-prepared EWH treatment [12–14,23]. The steatotic state was improved (reduced size and number of fat vesicles), but no histological changes were seen in the adipose tissue with the pepsin-prepared EWH groups presenting similar adipocyte size as the obese control [14]. Stearyl-CoA desaturase (SCD) is an enzyme involved in fat synthesis and responsible for converting a saturated fatty acid to its respective unsaturated fatty acid [12]. The SCD index is the ratio between those fatty acids and is related to obesity and insulin resistance. Dietary supplementation with protease-prepared EWH decreased SCD index in serum, muscle and liver in rodents [12,13,23].

Several hypotheses were tested in an attempt to elucidate the mechanisms responsible for reducing fat accumulation; for instance, SCD-1 is an enzyme essential in fat synthesis and because the abundance of lipogenic enzymes such as lipoprotein lipase (LPL) and fatty acids synthase (FAS) were not altered by EWH, the decrease in non-adipose tissue lipid content was attributed to the reduced SCD index [3]. Garcés-Rimon et al. postulate that the reduction in liver fat accumulation could be due to the ability of pepsin-prepared EWH to stimulate FFA oxidation in the hepatocytes but this hypothesis has not been tested [14]. Another possibility is that the reduction in fat accumulation occurred due to increased fat excretion. Indeed, two studies reported increased excretion of cholesterol (CHOL) and/or triglyceride (TG) and total bile acids in feces after protease-prepared EWH treatment [12,23]. In serum, reduction of CHOL or TG and/or free fatty acids (FFA) was observed [13,14,23]. However, no improvement in serum lipid profile was seen in another two studies [12,24].

An interesting corollary finding was that protease-prepared EWH increased muscular mass while decreasing fat accumulation, although the mechanism by which the hydrolysate acts remains unclear [13].

A study of the gut microbiota revealed that pepsin-prepared EWH treatment improved dysbiosis in obese rats; furthermore, short chain fatty acid (SCFA) and lactate concentrations in feces were lower compared to the obese group [15]. SCFAs are produced by gut microbiota through fermentation of dietary fiber, carbohydrates and peptides and are shown to improve glucose homeostasis and insulin sensitivity in rodents [25]; in addition, increased fecal SCFA content is found in obese human subjects [26]. Mechanisms that could explain the lower fecal SCFA in the pepsin-prepared EWH-fed group include maintenance of intestinal microbiota homeostasis or prevention of absorptive dysfunction by EWH; nevertheless, Requena et al. hypothesized that the change in microbiota occurred secondary to peptide absorption, with their actions on target tissues as antioxidant and anti-inflammatory agents leading to modulation of the gut microbiota [15] but there is as yet no evidence for this hypothesis.

Anti-inflammatory and antioxidant activity can contribute towards obesity and diabetes management [15]. In two studies in vivo, treatment with pepsin- and alcalase-prepared EWH reduced TNF-α in plasma and kidney and reduced malondialdehyde levels in plasma and urine indicating antioxidant properties [14,24]; these results are compatible with those observed in vitro previously mentioned in Table 1.
Table 2. In vivo studies of egg-derived hydrolysates/peptides and their effects related to diabetes and obesity in rodents.

| Egg white hydrolysate | Studies in rodents | Aims | Hydrolysis | Treatment Details | Food Intake and Body Weight (BW) | Blood/Feces/Urine Analysis | Tissue Analysis | Main Findings |
|-----------------------|-------------------|------|-------------|------------------|-------------------------------|---------------------------|-----------------|--------------|
| Wang et al., 2012 [5] | Zucker obese rats | Measure effect of hydrolysate NWT-03 on renovascular damage | Alcalase (6 h) | Aquacase NWT-03 (1 g/kg/day) 15 weeks | Food intake—not given BW—no effect | No effect on blood glucose, insulin, HBA1C, cholesterol and FFA levels. | KIDNEY—↓ inflammatory interleukins (IL-1β, IL-13) and TNF-α. Improved FGF-21 expression of α-SMA and ↓ TXA2R expression. | No changes in the diabetic profile of the rats; renovascular damage ↓ by NWT-03 treatment. |
| Ochiai and Matsuo 2014 [13] | Wistar rats | Investigate the effect of EW and EWH on fat metabolism and TG content in non-adipose tissues | Protease (duration not specified) | Casein (297 g/kg) EWH (394 g/kg) EW (286 g/kg) 8 weeks | Food intake EWH ↓ BW ↓ EWH vs. casin ↓ TG, ALP activity and FFA by EWH. EW vs. EWH ↓ HDL-CHOL, FFA and ↓ total CHOL by EWH. | FECEs ↑ | | |
| Requena et al., 2017 [15] | Zucker obese rats | Observe the effect of EWH on the gut microbiota of rats | Pepsin (8 or 14 h) | Aquacase EWH (750 mg/kg/day) 12 weeks | Food intake EWH ↓ BW ↓ | | | |

Abbreviations: EWH, Egg white hydrolysate; FFA, free fatty acids; MDA, Malondialdehyde; EW, Egg white; TG, Triglyceride; CHO, Cholesterol; ALP, Alkaline phosphatase; TBA, Total bile acids; SCD, Stearoyl CoA desaturase; NEFA, Non esterified fatty acids; FGS, Focal glomerulosclerosis; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; G6PDH, Glucose 6-phosphate dehydrogenase; LPL, Lipoprotein lipase; FAS, Fatty acid synthase; TNF-α, Tumor necrosis factor alpha; α-SMA, Anti-a-smooth muscle actin; VIL, Vildagliptin; HOMA-R, Homeostasis model assessment of insulin resistance; HOMA-β, Homeostasis model assessment of insulin secretion; GSH, Reduced Glutathione; HBA1C, Glycated hemoglobin; A1C; GLP-1, Glucagon like peptide-1; TXA2R, Thromboxane A2 receptor; SCFA, Short chain fatty acids; WK, week; ↑ enhanced/stimulated; ↓ reduced/inhibited.
When not treated, diabetes can lead to several complications including nephropathy. Although NWT-03, an alcalase-prepared EWH, exerted in vitro DPP IV-inhibitory activity, in vivo it was not efficient in improving the diabetic state; however, the treatment reduced renal injury development and albuminuria in T2D rats [24]. When compared with vildagliptin (VIL), a currently used DPP-IV inhibitor, both NWT-03 and VIL exerted renal protection effects but only VIL increased GLP-1 levels. Therefore, it is believed that NWT-03 and VIL can act via similar mechanisms but independently of their DPP-IV inhibitory activity [24].

It is worth noting that when administered in a single dose, protease-prepared EWH did not alter lipid profile, inhibit pancreatic lipase or slow food transit [23]. Interestingly, when compared, protease-prepared EWH and EW, both prevented fat accumulation and increased muscle mass, but EW increased fat excretion compared to EWH [13,23].

To summarize, EWH presented antidiabetic properties in vivo, reducing ectopic fat accumulation in liver and muscle, which can enhance insulin sensitivity, and increasing fat excretion, which reduces absorption of calories and could contribute to weight loss. It also protected against diabetes complications (nephropathy), but little or no change was observed regarding blood glucose, adiponectin or insulin levels and regarding inhibition of DPP-IV. The discrepancies in the results observed in vivo could be attributed to the difference in the physiological background of the animals used but is more likely due to variation in the mixture of peptides present in the hydrolysates. Furthermore, the studies suggest that bioactive peptides present in the EWH were responsible for at least part of the effects observed; nevertheless, no measurement of the peptides in plasma, identification of those peptides or any other specific assay was conducted. There is a gap in the literature to explain the mechanism of absorption and action of these peptides.

5. In Vitro Studies of Soy Hydrolysates (SH)/Peptides

Soybean also contains bioactive peptides, and eight studies evaluating the in vitro effects of SH or peptides against diabetes and obesity are summarized in Table 3. Similarly to EH, during adipocyte differentiation SH obtained from pepsin hydrolysis increased lipid accumulation, expression of PPAR-γ and the expression and secretion of adiponectin in a dose dependent manner in 3T3-L1 pre-adipocytes; furthermore, this SH enhanced glucose uptake and expression of GLUT4, which could contribute to improve insulin sensitivity [16]. It is believed that this SH stimulated pre-adipocyte differentiation through PPAR-γ activation, although the SH did not present PPAR-γ ligand activity [16]. Interestingly, a study found that compared to pepsin + pancreatin-prepared SH from ungerminated soybeans, using germinated soybean hydrolysate reduced the number of adipocytes during the differentiation process and increased lipolysis in mature adipocytes, which could lead to less fat accumulation [17]. Higher lipolysis in 3T3-L1 mature cells was observed after treatment with flavourzyme-prepared SH even after gastrointestinal (GI)-simulated digestion as well [8]. Along similar lines, SH prepared with alcalase lowered lipid accumulation and downregulated LPL and FAS gene expression (enzymes involved in the lipid uptake and de novo fatty acid synthesis) in the absence of or following GI-simulated digestion [18]. A hydrolysate obtained only with naturally-occurring GI enzymes (pepsin + pancreatin) exerted similar effects, although to a lesser extent. It suggests that GI digestion in vivo may not markedly affect the bioavailability of that SH [18] although whether that is true for all hydrolysates remains to be determined. β-conglycin is a storage protein naturally found in soybean and it is interesting to note that the higher the β-conglycin concentration in the hydrolysate, the higher the inhibition of LPL and FAS [18].

IR in skeletal muscle and liver is a prominent state found in T2D. Pepsin + pancreatin-prepared SH and its fractions (peptides not identified) enhanced glucose uptake in L6-muscle cells; in addition, the fractions, but not the SH, were able to activate AMPK pathway in those cells [9]. Glucose uptake in C2C12 skeletal muscle cells was also enhanced by another soy peptide, named aglycin [27]. In HepG2 cells soy peptides previously known to modulate cholesterol metabolism by activating AMPK and ERK1/2 pathway [28], affected glucose metabolism by enhancing AKT phosphorylation, which in
turn inactivated glycogen synthase kinase 3 (GSK3) by phosphorylating its serine residue, which can lead to higher glucose storage [29]. Moreover, the peptides increased glucose uptake and enhanced the expression GLUT4 and GLUT1 in liver cells [28]. One of these peptides (IAVPTGVA) also presented DPP-IV inhibitory activity with an IC₅₀ value of 106 µM, and the regions of interaction between IAVPTGVA and DPP-IV were identified as the amino terminal Glu205 and Glu206 and carboxyl terminal Arg358 residues [11].

Inflammation is not the focus of this review, but it is linked with obesity and diabetes. Two studies reported changes in inflammatory markers by SH [18] or soy peptide [30] in co-cultured adipocytes and macrophages such as, reduced COX-2 and inducible nitric oxide synthase protein and lowered nitric oxide and prostaglandin E2 production [18]. The treatment with synthetized soy peptide FLV reduced the production and effect of inflammatory molecules and improved insulin sensitivity in adipocytes (higher IRS-1 and AKT phosphorylation) [30]. The authors showed evidence that peptide transport into 3T3-L1 cells occurred mainly via the peptide transporter PepT2 [30].

Taken together, the in vitro results show that SH obtained after hydrolysis by specific enzymes and some identified peptides can improve insulin sensitivity, inhibit DPP-IV, increase glucose uptake in muscle and liver, and reduce lipid accumulation and inflammation in adipose tissue (Table 3). Some of the studies suggest that the soy peptides can act through AMPK and AKT pathways to modulate glucose metabolism and via PPAR-γ to stimulate adipocyte differentiation. Although one peptide transporter in adipocytes and regions of interaction between soy peptide and DPP-IV was identified [30], there is still a lack of studies regarding the specific interactions between the peptides and enzymes involved in the glucoregulation process and the mechanism of absorption of those peptides.
**Table 3. In vitro studies of soy-derived hydrolysates (SH)/peptides and their effects related to diabetes and obesity.**

| Soy specific peptides | Enzymatic activity | Hydrolysis | Outcomes | Main Findings | Peptides |
|-----------------------|-------------------|------------|----------|---------------|----------|
| Lammi et al., 2016 [11] | Verify that soy peptide inhibits DPP-IV in vitro and identify the regions of interactions | Pepsin and/or Pancreatin synthesized peptides | Only IAVPTGVA ↓ DPP-IV activity. Regions of interaction were n-terminal Glu205 and Glu206 and c-terminal Arg358; the peptide has a proline flanked by valine in the fourth n-terminal residue, predicts interaction with DPP-IV. | Soy peptide IAVPTGVA ↓ DPP-IV activity in vitro. YVVNPDEN and YYVFNPPDEN were inactive against DPP-IV. | IAVPTGVA YVVNPDEN YYVFNPPDEN |
| Soy specific peptides | | | | | |
| Lammi et al., 2015 [29] | Verify that soy peptides modulate glucose metabolism | Trypsin or pepsin - synthesized peptides | All three peptides ↑ p-AKT, ↓ GSK3 activation, ↑ GLUT4 and GLUT1 mRNA, ↑ glucose uptake. IAVPTGVA > IAVPGEVA > LPYP. IAVPGEVA and IAVPTGVA ↑ GLUT1 mRNA more; LPYP ↑ GLUT4 mRNA more. | Soy peptides modulate glucose metabolism and ↑ glucose uptake in liver cells by activation of AKT and AMPK pathways. | IAVPGEVA IAVPTGVA LPYP |
| Tsou et al., 2013 [8] | Isolate and identify peptides from soy hydrolysate with lipolytic activity | Flavourzyme 1% (125 min) | Three peptides ↑ glycerol release. After in vitro GI simulated digestion, VHVV capacity was not affected; ILL and LLL had attenuated lipolytic activity. | Soy peptides ↑ lipolysis in 3T3-L1 adipocytes and were little or not affected by GI enzymes. | ILL LLL VHVV |
| Kuak et al., 2016 [30] | Demonstrate the mechanism of transport of soy peptide into adipocytes and evaluate TNF-α induced inflammation and insulin response | Synthetic peptide | FLV peptide ↓ TNF-α, MCP-1 and IL-6 in co-cultured cell line (macrophages + adipocytes). FLV ↓ TNF-α-induced p-JNK and p-IKK and ↓ degradation of IκBα. TNF-α induced insulin resistance in adipocytes was ameliorated by FLV (↑ p-IRS-1, p-AKT). PepT2 > PepT1 expressed in adipocytes, ↑ by LPS and TNF-α. | FLV is transported into adipocyte cells mainly through PepT2 action and FLV can ↓ the inflammatory and insulin resistant states linked to obesity mainly by ↓ TNF-α-induced inflammatory pathways. | FLV |
| Soy Hydrolysate | | | | | |
| Martinez-Villaluenga et al., 2009 [18] | Study the effect of SH on lipid accumulation and inflammation | Alcalase (3 h) or Pepsin + Pancreatin (3 h each) | Alcalase SH in 3T3-L1 cells: ↓ lipid accumulation, LPL and FAS mRNA. Further GI simulated digestion did not reduce the bioavailability of Alcalase SH. Compared to Pepsin + pancreatin SH, Alcalase SH ↓ LPL and FAS mRNA in a higher extension, before and after GI digestion. Alcalase SH in RAW cells: ↓ LPL-induced nitrite formation, iNOS and COX-2 protein expression, PGE2 production. Alcalase SH in 3T3-L1 cells: ↓ lipid accumulation, LPL mRNA, but not FAS mRNA. | SH ↓ lipid accumulation and inflammatory marker expression, even after GI simulated digestion. Downregulation of LPL and FAS partially explain mechanism of action. Higher concentration of β-conglycin in the hydrolysate related to higher activity in vitro. | N/A |
### Table 3. Cont.

| Aims | Hydrolysis | Outcomes | Main Findings | Peptides |
|------|------------|----------|---------------|----------|
| **Soy specific peptides**<br>Enzymatic activity | Investgate the effect of germinated vs. ungerminated soybean hydrolysate on fat metabolism in adipocytes. Assess the interaction with soy phytochemicals. | Pepsin + Pancreatin (duration not specified) | Concentration > 1 mg/mL ↓ cell viability during differentiation process (10 days incubation), but not during 24 h of exposure. SH with and without phytochemicals ↓ lipogenesis, with higher germination time correlated to greater lipogenesis reduction. Lipolysis were present in a dose-dependent manner only with SH without phytochemicals treatment. | Germination changed the amino acids composition in the SH and interfered with the responses. Overall, SH ↓ the number of adipocytes during the differentiation process and ↑ lipolysis in mature adipocytes. |
| **González-Espinosa de los Monteros et al., 2011 [17]**<br>3T3-L1 adipocytes | SH with and without phytochemicals ↓ lipogenesis, with higher germination time correlated to greater lipogenesis reduction. Lipolysis were present in a dose-dependent manner only with SH without phytochemicals treatment. | | N/A |
| **Goto et al., 2013 [16]**<br>3T3-L1 pre-adipocytes | Observe effects of soybean peptic hydrolysate on adipocyte differentiation | Peptic hydrolysate (duration and enzymes not specified) | SH ↑ adipocyte differentiation via PPAR-γ pathway and ↑ glucose uptake during differentiation process. | N/A |
| **Roblet et al., 2014 [9]**<br>L6-skeletal muscle cells | Verify the potential of EDUF to concentrate soy peptides and identify the mechanism of action of those peptides | Pepsin (45 min) + Pancreatin (120 min) | The initial hydrolysate, anionic and cationic peptides ↑ glucose uptake. Only the peptides ↑ p-AMPK. | |
6. In Vivo Studies of Soy Hydrolysate (SH)/Peptides

The tests in vivo described in Table 4 show that SH can modulate glucose metabolism and reduce body weight. Two studies reported reduced blood glucose levels by SH or peptides [27,31]. Similarly to in vitro studies (Table 3), a 37-amino acid soy peptide named aglycin improved muscle glucose uptake by increasing the phosphorylation of insulin receptor, IRS-1 and AKT, and enhancing membrane GLUT4 levels, which contribute to improved insulin sensitivity in T2D mice [27]. In fact, treatment with aglycin led to similar results as those exerted by metformin in oral glucose tolerance (OGTT) and insulin tolerance tests [27]; furthermore, the release of insulin during OGTT was normal in the treated animals and, as expected, abnormal in T2D mouse controls, suggesting that the effect on glucose tolerance was primarily due to enhanced glucose uptake and insulin sensitivity [27]. It is noteworthy that intact aglycin-37 amino acids were found in blood samples from mice, indicating that it is stable after GI digestion and probably absorbed intact [27].

With regards to serum lipid profile and lipid excretion, protease-prepared SH reduced fat accumulation in genetically obese mice, enhanced lipid excretion and improved plasma CHOL levels in diet obese rats [31]. The reduction in fat accumulation could be due to the higher postprandial energy expenditure observed after intake of protease-prepared SH compared to casein [32]; furthermore, the major contributor to enhanced postprandial energy expenditure was increased exogenous carbohydrate oxidation. Although the effect on energy expenditure was not sustained after 24 h, total carbohydrate oxidation continued to be higher in the SH-treated group, perhaps due to higher plasma insulin levels and lower glucose concentrations during the postprandial period or due to lower lipid absorption and increased carbohydrate absorption [32]. No experiments were conducted to substantiate these hypotheses.

Tests in humans have only been done with respect to glucagon and insulin responses after intake of SH or intact soy protein. SH induced a slower response of insulin and glucagon compared to its intact protein and no effect in plasma glucose was observed. The concentration of soy protein or SH administered did not correlate with the increase in plasma levels of insulin but, interestingly, glucagon was sensitive to protein concentration in a dose-dependent manner for both soy groups [33]. Another comparison, in rodents, showed that SH reduced body weight compared to whey isolate (WI) and whey isolate hydrolysate (WIH). In addition, soy intact protein and SH reduced liver and fat pad weight and maintained body protein percentage compared to WIH and WI, respectively [34].

The results in vivo herein, although scarce show that SH and soy peptides can potentially reduce tissue fat accumulation and increase fat excretion. Moreover, the soy peptide aglycin is resistant to GI digestion and can be absorbed intact by mice [27]. SH may also facilitate metabolic flexibility by shifting to carbohydrate utilization [32]. Nevertheless, only a few studies were done to test SH and peptides as antidiabetic agents in vivo and only one identified the peptide responsible for the effects.

7. Conclusions

In conclusion, the research so far shows that both egg and soybean can be rich sources of bioactive peptides; furthermore, they can potentially exert multiple physiological activities, including anti-obesity and anti-diabetic effects, which is relevant in the management of MetS. Bioactive peptides can be produced by different methods such as, enzymatically, chemically or by molecular biology. However, there is a huge variability in the methods, consequently generating many different hydrolysates and peptides, as shown in Tables 1–4. The duration of the hydrolysis process and the enzymes used generate different amino acid sequences, which influence the type and intensity of activity exerted by the peptides. Although an in silico approach may help to investigate the predictability of peptide generation [11], the predictability, purity and cost-effectiveness of each method vary [35]; therefore, optimization of the production process and the identification of amino acid sequences that can potentially act as anti-diabetic agents are still in need.
### Table 4. In vivo studies of soy-derived hydrolysates/peptides and their effects related to diabetes and obesity.

| Aims | Hydrolysis | Treatment Details | Feed Intake and Body Weight (BW) | Blood/Feces/Urine Analysis | Tissue Analysis | Main Findings |
|------|------------|-------------------|---------------------------------|---------------------------|----------------|---------------|
| **Soy Specific peptide**<br>Studies in rodents | | | | | | |
| Lu et al., 2011 [27]<br>BALB/c mice | Investigate effects of soy peptide aglycin as antidiabetic agent | Not specified | HFD + aglycin (50 mg/g) or Metformin (100 mg/kg/d) orally daily for 28 days | No difference in BW or food intake (compared with diabetic model control) | Intact peptide detected in plasma after oral administration. Glucose after 28 days ↓ by Aglycin. OGTT and ITT- Aglycin similar effect as metformin. Insulin release not affected during OGTT. | Skeletal Muscle ↑ mRNA and total protein of IR and IRS-1. Total AKT and GLUT 4 mRNA not different. ↑ p-IR, p-IRS-1, p-AKT and GLUT4 on membrane. Aglycin ameliorated glucose intolerance and insulin resistance in T2D mice mainly by ↑ glucose utilization and insulin sensitivity after long-term treatment. Aglycin - glucone uptake ↑ in C2C12 skeletal muscle by aglycin in normal and insulin resistant cells. |
| **Soy hydrolysate**<br>Studies in rodents | | | | | | |
| Aoyama et al., 2000 [31]<br>Sprague-Dawley rats | Study the effect of soy isolate hydrolysate on weight reduction | Protease (duration not specified) | HFD for 12 weeks + SH (40.4%) or SPI or Casein (39.1%) for 4 weeks | No difference in BW, food intake (compared with HFD control) | SP X SH - similar | SH ↓ fat accumulation and blood lipid profile levels by ↑ fat excretion. SH ↓ blood glucose in rats. |
| Yellow KK mice | Study the effect of intact soy protein and hydrolysate as anti-obesity agents | Protease (duration not specified) | HFD for 31 days + SH (40.4%) or Casein (39.1%) for 4 weeks | No difference in BW, food intake (compared with HFD control) | SP and SH ↓ % fat and ↑ % protein (body composition). | SH ↓ fat accumulation and ↑ total protein % in genetically obese KK mice. |
| Aoyama et al., 2000 [34]<br>Yellow KK mice | Study the effect of intact soy protein and hydrolysate as anti-obesity agents | Protease (duration not specified) | HFD for 4 weeks + SPI or SPIH or WI or WHH for 2 weeks (energy restricted diet) | ↑ BW and carcass weight than WI and WHH | SH X Casein-SPH | No differences were observed between the SP and SH groups; however, compared to WI and WHH. SH ↓ weightgain, liver and fat pad weight while maintaining body protein. |
| Ishihara et al., 2003 [32]<br>Yellow KK mice | Investigate the effect of soy isolate hydrolysate on energy expenditure | Protease (duration not specified) | HFD for 28 days + high protein diet SH (444.4 g/kg) or Casein (391 g/kg) for 4 weeks | No difference in BW or food intake | SH ↓ lipid content | SH ↓ postprandial energy expenditure, ↑ exogenous carbohydrate oxidation. No difference in postprandial endogenous lipid oxidation. 24-h energy expenditure similar; ↑ 24-h carbohydrate oxidation. SH exerted more TG in feces than caserin group. |
| **Soy hydrolysate**<br>Studies in Humans | | | | | | |
| Claessens et al., 2008 [33]<br>Male, non-obese human (average 28 years, BMI 24 Kg/m²) | Compare glucagon and insulin response after ingestion of soy protein and SH | Not specified | Cross-over trial: consumed drinks containing 0.3, 0.4 or 0.6 g/kg BW of soy protein or SH | ↑ for insulin and glucagon response. Blood glucose not different. Enhanced effect on glucagon response with increased protein load during intact and SH ingestion than on insulin response. | N/A | N/A |

Abbreviations: IRS-1, Insulin receptor substrate 1; AKT, protein kinase B; GLUT4, Glucose transporter 4; SPH, Soy hydrolysate; SP, intact soy protein; HFD, High fat diet; CHOL-cholesterol; TG, Triglyceride; OGTT, Oral glucose tolerance test; ITT, Insulin tolerance test; T2D, Type 2 diabetes; BW, Body weight; BMI, Body mass index; WK, week; ↑ enhanced/stimulated; ↓ reduced/inhibited.
In addition, the treatment length and the use of animals with different physiological and genetic backgrounds, such as obesity, diabetes and normal physiology contributed to the discrepancies in the results observed in vivo, which indicates the need of a standardized physiological model to better evaluate the activity of the peptides in diabetic states. Despite these limitations, it is clear that a wide variety of peptides from egg and soybean have overlapping biological activities that may be useful in the treatment of diabetes or obesity.

A weak correlation between the studies mentioned in this review and clinical trials could be drawn. Only one clinical trial using egg peptides was identified and it showed that NWT-03, an egg peptide previously mentioned in this review [24], reduced blood pressure in mild-hypertensive subjects [36]. In terms of soy, only data from clinical trials using black soy peptides were found. Black soy peptides reduced 2h-OGTT, weight, fat mass, leptin levels, blood pressure and oxidative stress in Korean subjects [37–39]. At this time, no data from clinical trials associating egg hydrolysate/peptides and glucose metabolism were found.

Even though some investigation of the effects of EH and SH on markers of diabetes and obesity have been done, there is still a lack of studies with focus on the mechanisms of absorption and action of the peptides, especially related to their interaction with cellular and molecular targets involved in insulin and glucose metabolism. Therefore, more studies are necessary to elucidate the effect of EH and SH and their real potential as functional food ingredients to be implemented in the management of obesity and T2D.

Author Contributions: S.C.d.C.Z. wrote the paper; J.W. and C.B.C. edited the paper.

Acknowledgments: This work is supported by research grants from the Alberta Livestock and Meat Agency, Egg Farmers of Canada, and the Natural Sciences and Engineering Research Council of Canada.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. World Health Organization (WHO). Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation; WHO Press: Geneva, Switzerland, 2006; p. 5. ISBN 92-4-1594934.
2. World Health Organization (WHO). Global Report on Diabetes; WHO Press: Geneva, Switzerland, 2016; p. 13, ISBN 978-92-4-156525.
3. García-Pérez, L.-E.; Álvarez, M.; Dilla, T.; Gil-Guillén, V.; Orozco-Beltrán, D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013, 4, 175–194. [CrossRef] [PubMed]
4. European Commission Concerted Action on Functional Food Science in Europe (FUFOSE). Scientific concepts of functional foods in Europe consensus document. Br. J. Nutr. 1999, 81, S1–S27. [CrossRef]
5. Liu, Y.; Oey, I.; Bremer, P.; Carne, A.; Silcock, P. Bioactive peptides derived from egg proteins: A review. Crit. Rev. Food Sci. Nutr. 2017, 1–23. [CrossRef] [PubMed]
6. Masilamani, M.; Wei, J.; Sampson, H.A. Regulation of the immune response by soybean isoflavones. Immuno. Res. 2012, 54, 95–110. [CrossRef] [PubMed]
7. Zambrowicz, A.; Pokora, M.; Setner, B.; Dąbrowska, A.; Szöltyssik, M.; Babij, K.; Szewczuk, Z.; Trziszka, T.; Lubec, G.; Chrzanowska, J. Multifunctional peptides derived from an egg yolk protein hydrolysate: Isolation and characterization. Amino Acids 2015, 47, 369–380. [CrossRef] [PubMed]
8. Tsou, M.J.; Kao, F.J.; Lu, H.C.; Kao, H.C.; Chiang, W.D. Purification and identification of lipolysis-stimulating peptides derived from enzymatic hydrolysis of soy protein. Food Chem. 2013, 138, 1454–1460. [CrossRef] [PubMed]
9. Roblet, C.; Doyen, A.; Amiot, J.; Pilon, G.; Marette, A.; Bazinet, L. Enhancement of glucose uptake in muscular cell by soybean charged peptides isolated by electrodialysis with ultrafiltration membranes (EDUF): Activation of the AMPK pathway. Food Chem. 2014, 147, 124–130. [CrossRef] [PubMed]
10. Son, M.; Chan, C.B.; Wu, J. Egg white ovotransferrin-derived ACE inhibitory peptide ameliorates angiotensin II-stimulated insulin resistance in skeletal muscle cells. Mol. Nutr. Food Res. 2017. [CrossRef] [PubMed]
11. Lammi, C.; Zanoni, C.; Arnoldi, A.; Vistoli, G. Peptides derived from soy and lupin protein as dipeptidyl-peptidase IV inhibitors: In vitro biochemical screening and in silico molecular modeling study. *J. Agric. Food Chem.* 2016, 64, 9601–9606. [CrossRef] [PubMed]

12. Ochiai, M.; Kuroda, T.; Matsu, T. Increased muscular triglyceride content and hyperglycemia in Goto-Kakizaki rat are decreased by egg white hydrolysate. *Int. J. Food Sci. Nutr.* 2014, 65, 495–501. [CrossRef] [PubMed]

13. Ochiai, M.; Matsu, T. Effect of egg white and its hydrolysate on stearyl-CoA desaturase index and fat accumulation in rat tissues. *Int. J. Food Sci. Nutr.* 2014, 65, 948–952. [CrossRef] [PubMed]

14. García-Rimón, M.; González, C.; Uranga, J.A.; López-Miranda, V.; López-Fandiño, R.; Miguel, M. Pepsin egg white hydrolysate ameliorates obesity-related oxidative stress, inflammation and steatosis in Zucker fatty rats. *PLoS ONE* 2016, 11, e0151193. [CrossRef] [PubMed]

15. Requena, T.; Miguel, M.; García-Rimón, M.; Martínez-Cuesta, M.C.; López-Fandiño, R.; Peláez, C. Pepsin egg white hydrolysate modulates gut microbiota in Zucker obese rats. *Food Funct.* 2017, 8, 437–443. [CrossRef] [PubMed]

16. Goto, T.; Mori, A.; Nagaoka, S. Soluble soy protein peptic hydrolysate stimulates adipocyte differentiation in 3T3-L1 cells. *Mol. Nutr. Food Res.* 2013, 57, 1435–1445. [CrossRef] [PubMed]

17. González Espinosa de los Monteros, L.A.; Ramón-Gallegos, E.; Torres-Torres, N.; Mora-Escobedo, R. Effect of germinated soybean protein hydrolysates on adipogenesis and adipolysis in 3T3-L1 cells. *Plant Foods Hum. Nutr.* 2011, 66, 355–362. [CrossRef] [PubMed]

18. Martínez-Villaluenga, C.; Dia, V.P.; Berhow, M.; Bringe, N.A.; de Mejía, E.G. Protein hydrolysates from β-conglycinin enriched soybean genotypes inhibit lipid accumulation and inflammation in vitro. *Mol. Nutr. Food Res.* 2009, 53, 1007–1018. [CrossRef] [PubMed]

19. García-Rimón, M.; López-Expósito, I.; López-Fandiño, R.; Miguel, M. Egg white hydrolysates with in vitro biological multiactivities to control complications associated with the metabolic syndrome. *Eur. Food Res. Technol.* 2016, 242, 61–69. [CrossRef]

20. Jahandideh, F.; Chakrabarti, S.; Davidge, S.T.; Wu, J. Egg white hydrolysate shows insulin mimetic and sensitizing effects in 3T3-F442A pre-adipocytes. *PLoS ONE* 2017, 12. [CrossRef] [PubMed]

21. Miner-Williams, W.M.; Stevens, B.R.; Moughan, P.J. Are intact peptides absorbed from the healthy gut in the adult human? *Nutr. Res. Rev.* 2014, 27, 308–329. [CrossRef] [PubMed]

22. Yu, Z.; Yin, Y.; Zhao, W.; Yu, Y.; Liu, B.; Liu, J.; Chen, F. Novel peptides derived from egg white protein inhibiting alpha-glucosidase. *Food Chem.* 2011, 129, 1376–1382. [CrossRef]

23. Ochiai, M.; Misaki, K.; Takeuchi, T.; Narumi, R.; Azuma, Y.; Matsu, T. Egg white hydrolysate can be a low-allergenic food material to suppress ectopic fat accumulation in rats fed an equicaloric diet. *J. Nutr.* 2016, 146, 111–119. [CrossRef] [PubMed]

24. Wang, Y.; Landheer, S.; van Gilst, W.H.; van Ameijden, A.; Hammes, H.P.; Henning, R.H.; Deelman, L.E.; Buijken, H. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory activity. *PLoS ONE* 2012, 7, 1–11. [CrossRef] [PubMed]

25. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefèvre, M.; Cefallu, W.T.; Ye, J. Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice. *Diabetes* 2010, 58, 1–14. [CrossRef] [PubMed]

26. Schwier, A.; Taras, D.; Schäfer, K.; Beijer, S.; Bos, N.A.; Donus, C.; Hardt, P.D. Microbiota and SCFA in lean and overweight healthy subjects. *Obesity* 2010, 18, 190–195. [CrossRef] [PubMed]

27. Lu, J.; Zeng, Y.; Hou, W.; Zhang, S.; Li, L.; Luo, X.; Xi, W.; Chen, Z.; Xiang, M. The soybean peptide aglycin regulates glucose homeostasis in type 2 diabetic mice via IR/IR1 pathway. *J. Nutr. Biochem.* 2012, 23, 1449–1457. [CrossRef] [PubMed]

28. Lammi, C.; Zanoni, C.; Arnoldi, A. IAVPGEVA, IAVPTGVA, and LYPY, three peptides from soy glycinein, modulate cholesterol metabolism in HepG2 cells through the activation of the LDLR-SREBP2 pathway. *J. Funct. Foods* 2015, 14, 469–478. [CrossRef]

29. Lammi, C.; Zanoni, C.; Arnoldi, A. Three peptides from soy glycinein modulate glucose metabolism in human hepatic HepG2 cells. *Int. J. Mol. Sci.* 2015, 16, 27362–27370. [CrossRef] [PubMed]

30. Kwak, S.-J.; Kim, C.-S.; Choi, M.-S.; Park, T.; Sung, M.-K.; Yun, J.W.; Yoo, H.; Mine, Y.; Yu, R. The soy peptide Phe–Leu–Val reduces TNFα-induced inflammatory response and insulin resistance in adipocytes. *J. Med. Food* 2016, 19, 678–685. [CrossRef] [PubMed]
31. Aoyama, T.; Fukui, K.; Takamatsu, K.; Hashimoto, Y.; Yamamoto, T. Soy protein and its hydrolysate reduce body fat of dietary obese rats and generically obese mice (yellow KK). *Nutrition* 2000, 16, 349–354. [CrossRef]
32. Ishihara, K.; Oyaizu, S.; Fukuchi, Y.; Mizunoya, W.; Segawa, K.; Takahashi, M.; Mita, Y.; Fukuya, Y.; Fushiki, T.; Yasumoto, K. A soybean peptide isolate diet promotes postprandial carbohydrate oxidation and energy expenditure in type II diabetic mice. *J. Nutr.* 2003, 133, 752–757. [CrossRef] [PubMed]
33. Claessens, M.; Saris, W.H.; van Baak, M.A. Glucagon and insulin responses after ingestion of different amounts of intact and hydrolyzed proteins. *Br. J. Nutr.* 2008, 100, 61–69. [CrossRef] [PubMed]
34. Aoyama, T.; Fukui, K.; Nakamori, T.; Hashimoto, Y.; Yamamoto, T.; Takamatsu, K.; Sugano, M. Effect of soy and milk whey protein isolates and their hydrolysates on weight reduction in genetically obese mice. *Biosci. Biotechnol. Biochem.* 2000, 64, 2594–2600. [CrossRef] [PubMed]
35. Zambrowicz, A.; Timmer, M.; Polanowski, A.; Lubeč, G.; Trziszka, T. Manufacturing of peptides exhibiting biological activity. *Amino Acids* 2013, 44, 315–320. [CrossRef] [PubMed]
36. Plat, J.; Severins, N.; Morrison, S.; Mensink, R.P. Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: A dose-finding study. *Br. J. Nutr.* 2017, 117, 942–950. [CrossRef] [PubMed]
37. Kwak, J.H.; Lee, J.H.; Ahn, C.W.; Park, S.H.; Shim, S.T.; Song, Y.D.; Han, E.N.; Lee, K.H.; Chae, J.S. Black Soy Peptide Supplementation Improves Glucose Control in Subjects with Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus. *J. Med. Food* 2010, 13, 1307–1312. [CrossRef] [PubMed]
38. Kwak, J.H.; Ahn, C.W.; Park, S.H.; Jung, S.U.; Min, B.J.; Kim, O.Y.; Lee, J.H. Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: Double blind, randomized, controlled study. *Food Funct.* 2012, 3, 1019. [CrossRef] [PubMed]
39. Kwak, J.H.; Kim, M.; Lee, E.; Lee, S.H.; Ahn, C.W.; Lee, J.H. Effects of black soy peptide supplementation on blood pressure and oxidative stress: A randomized controlled trial. *Hypertens. Res.* 2013, 36, 1060–1066. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).